BPC-157: Research Overview

The short version

BPC-157 (short for Body Protection Compound 157) is a synthetic 15-amino-acid peptide copied from part of a protein found in human gastric (stomach) juice. In animal studies it has been linked to faster healing of tendons, ligaments, and stomach-lining injuries, largely by promoting the growth of new blood vessels (angiogenesis).

Almost everything known about BPC-157 comes from rats, dogs, and lab cell cultures. As of 2025, only three small human pilot studies exist, and a 2025 review says rigorous, large-scale human trials are still lacking ^[2]. It is not an approved medicine anywhere, and it's sold only as a research chemical, not for human consumption. Nothing on this page is a recommended dose or a treatment suggestion — it summarizes what has actually been studied, and where the evidence stops.

What it is

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (molecular formula C62H98N16O22). It's derived from a partial sequence of a human gastric-juice protein called BPC, and it goes by several names in the literature and on supplier labels, including Pentadecapeptide BPC 157, PL 14736, and PLD-116. Its category in the research literature is a 'stable gastric pentadecapeptide' — stable meaning it resists the rapid breakdown that would normally happen to a fragment this size once released into digestive fluid or the bloodstream, at least long enough to produce measurable effects in animal models.

How it works

BPC-157 is described in the literature as a cytoprotective peptide — one that protects and helps repair tissue — and its effects in animal models are most consistently tied to angiogenesis, the growth of new blood vessels. The best-characterized pathway is up-regulation of the VEGFR2 receptor (a receptor tied to vessel growth) along with its internalization into cells, triggering downstream VEGFR2-Akt-eNOS signaling, which increases nitric oxide and supports new vessel formation ^[4]. Other reported routes include the FAK-paxillin pathway (involved in cell migration), sensitization of the growth-hormone receptor in tendon fibroblasts, the cells that build tendon tissue ^[6], and effects on the nitric-oxide system and several neurotransmitter systems, including serotonin and dopamine, that researchers link to a proposed 'brain-gut axis' role ^[7].

What the research shows

A first-in-human safety pilot. In 2025, two healthy adults (a 58-year-old man and a 68-year-old woman) received intravenous BPC-157 up to 20 mg. It was well tolerated, with no adverse events and no measurable changes in cardiac, liver, kidney, thyroid, or glucose biomarkers — though a two-person study cannot establish effectiveness, only that this small dose was tolerated in this tiny sample ^[1].

The state of human evidence, honestly. A 2025 narrative review found only three pilot human studies of BPC-157 in the entire published literature, concluded that rigorous, large-scale trials are lacking, and recommended treating BPC-157 as investigational given the regulatory controversy and unregulated availability of research-chemical products ^[2].

Pharmacokinetics — how fast it clears. The first formal characterization of BPC-157's pharmacokinetics, in rats and beagle dogs, found linear kinetics, an elimination half-life under 30 minutes, and modest bioavailability via intramuscular injection (about 14-19% in rats, 45-51% in dogs), with rapid breakdown into small fragments that enter normal amino-acid metabolism ^[3].

The foundational animal findings. In Wistar rats, BPC-157 reduced gastric ulcer area and sped ulcer healing, with intramuscular delivery working better than intragastric delivery ^[5]. In a separate rat study, it accelerated healing of a fully transected Achilles tendon across biomechanical, functional, and microscopic measures, and stimulated tendon-cell growth in a lab dish ^[6]. Vessel-growth studies in chick membranes, ischemic rat hindlimbs, and human endothelial cells found BPC-157 increased vessel density and blood-flow recovery, and that blocking cell uptake blocked the effect ^[4].

Reported effects, cautions & safety

The following benefits and side effects are reported by people in research-use communities. They are anecdotal, not clinical evidence, and none of them come with a stated dose.

Reported benefits: The most common reason people describe trying BPC-157 is faster recovery from tendon, ligament, and joint injuries — tennis elbow, rotator-cuff strain, old sprains — often noticing improvement within one to three weeks. Many also describe less joint stiffness, easier digestion, a general sense of reduced inflammation, faster healing of minor skin wounds, and better sleep or mood. All of these are personal accounts, not results from controlled human trials.

Reported side effects: The most common complaint is a local injection-site reaction — brief stinging, redness, or a small bump that people say fades within a day. A minority report mild nausea or stomach upset, more often with oral products than injections. Less common reports include first-week fatigue, headache, brief dizziness after injecting, a wave of warmth or flushing, and — rarely — heart palpitations, which several sources describe as a reason to stop and seek medical evaluation.

Cited safety cautions from the literature:

• The human evidence is extremely thin. Nearly everything known comes from rodents; only a handful of small human pilots exist, and large controlled trials are lacking ^[2].
• Much of the foundational research comes from one research group, limiting independent replication ^[2].
• It is not an approved drug, and unregulated research-chemical products carry no verified purity or dose ^[2].
• Strong pro-angiogenic activity raises a theoretical cancer concern, since tumors also depend on new blood vessels — this is mechanism-based reasoning, not a human finding ^[4].
• A possible interaction with serotonin-affecting medicines is suggested by rodent data connecting BPC-157 to serotonin activity, though no human interaction study exists ^[7].
• It's prohibited in competitive sport by the World Anti-Doping Agency's non-approved-substances category.

Where BPC-157 fits in research peptide fundamentals

BPC-157 is this site's illustration of a protein fragment turned research peptide: a 15-amino-acid slice of a much larger gastric protein, stable enough to survive long enough to act, but with a research record that is overwhelmingly animal-based. Compare that origin story with GHK-Cu and KPV, both even shorter three-amino-acid fragments, or with semaglutide, which starts from a hormone and is deliberately engineered rather than isolated. See the full comparison for how all four stack up.